CD274 and ovarian cancer: The first preclinical study evaluating PARPi veliparib in combination with anti-PD1/PD-L1 in the BRCA1-deficient BR5 mouse ovarian cancer model observed no significant boost in T cell activity and no improvement in survival [146].